Screener
BridgeBio Pharma BBIO Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $1,370,981 | $936,025 |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $29,058 | $36,228 |
| Accrued compensation and benefits | 39,338 | 76,703 |
| Accrued research and development liabilities | 54,430 | 41,436 |
| Operating lease liabilities, current portion | 4,439 | 6,192 |
| Deferred revenue, current portion | 6,115 | 7,190 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's accounts payable?
- BridgeBio Pharma (BBIO) reported accounts payable of $29.06M in Q1 2026.
- How has BridgeBio Pharma's accounts payable changed year-over-year?
- BridgeBio Pharma's accounts payable increased by 5.6% year-over-year, from $27.53M to $29.06M.
- What is the long-term trend for BridgeBio Pharma's accounts payable?
- Over 5 years (2020 to 2025), BridgeBio Pharma's accounts payable has grown at a 32.3% compound annual growth rate (CAGR), from $8.95M to $36.23M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about BridgeBio Pharma's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude